 |
|
|
|||||
Today, Bed Bath & Beyond will be trading on the New York Stock Exchange under its former ticker symbol BBBY. But no, you havent missed the home goods retailer’s initial public offering. The brands owner, Beyond, has decided to change its company name to that of its most iconic retail brand and, with that change, adopt the former Bed Bath & Beyond ticker as its own stock symbol. Heres what you need to know about the return of BBBY to the stock market. Whats happened? In mid-August, Beyond, the owner of the Bed Bath & Beyond, Overstock, and Buybuy Baby brands, announced that it would change its company name to Bed Bath & Beyond, with the stock ticker changing when the market opens on Friday, August 29. That’s today. The company’s previous ticker was BYON. The newly renamed Bed Bath & Beyond stock under the old BBBY ticker will continue to trade on the NYSE. So in short: Beyond has changed its corporate name to Bed Bath & Beyond The company is also changing its stock ticker from BYON to BBBY. The revival of Bed Bath & Beyond The name change of Beyond to Bed Bath & Beyond and the ticker change from BYON to BBBY are just the latest moves by the company as it aims to revive the Bed Bath & Beyond brand. The once ubiquitous home goods retailer, which was a staple of suburban shopping landscapes in the early 2000s, struggled, like many retailers, with changing consumer shopping habits, rising costs, and declining foot traffic. In 2023, the chain filed for bankruptcy, and the brand was acquired by Overstock.com, which Beyond owns. Early this month, Beyond teamed with retail operator The Brand House Collective to reopen a physical Bed Bath & Beyond store in Nashvillethe first Bed Bath & Beyond store the country has seen in years. Beyond says the new sole store has experienced significant traffic and revenue alongside nationwide media coverage. And it doesnt seem that the Nashville Bed Bath & Beyond will be the sole location for long. CEO Marcus Lemonis has claimed that up to 300 more Bed Bath & Beyond locations are in the works. (He has also been embroiled in a dispute with California Governor Gavin Newsom, stating that while 300 more stores are planned, none will be located in California due to the state’s regulations.) Addressing the corporate name change from Beyond to Bed Bath & Beyond, Lemonis said, Our name change is highlighting one of the most valuable pieces of intellectual property that investors and consumers know today and does not change our intense focus on growing revenue, achieving profitability in the near term, and monetizing valuable blockchain assets. A nostalgia and meme play? Bed Bath & Beyond is arguably the most recognizable IP that Beyond owns, so it makes sense to rename the company after it, especially if a major retail expansion is planned. However, the companys use of the old stock ticker might seem to some observers as a little more forced. We already know that Bed Bath & Beyond isnt afraid to play the nostalgia card, which it is already doing with its Nashville reopening by allowing customers who have old, expired Bed Bath & Beyond coupons to use them at the new location. One cant help but speculate that the ticker change from BYOD to the old BBBY may be a nostalgia play in hopes that it will give shares a boostespecially from meme stock investors. Before the retailer filed for bankruptcy, BBBY had been a favorite meme stock, alongside such legacy companies as GameStop, BlackBerry, and AMC. It will be interesting to see how the stock reacts today, its first trading day under the new symbol, once markets open. Yesterday, BYOD shares closed their last trading day under that ticker, up 3.51% for the day to $9.44. As of yesterdays close, BYOD had already had a terrific run year to date, with the stock surging more than 91% in 2025 so far. However, over the past 12 months, BYOD shares have declined by more than 7.5%. Could the stock make up those losses once its ticker symbol changes to BBBY today? Only time will tell.
Category:
E-Commerce
We spend so much time at work, its natural that we strike up friendships with colleagues. Its common, and research shows its even good for your career and happiness. But what happens when your office pals performance drags the team down, causes inefficiencies, or more work for you? How do you bring it up . . . and should you? Its a tricky needle to thread, but experts provide tips for fielding these potentially awkward conversations with your office ride-or-die. The complex friendship dynamic When a colleague feels more like a friend, it can make a discussion about their laziness more difficult, says Leanna Stockard, a licensed therapist with LifeStance Health, one of the countrys biggest mental healthcare providers. Given the amount of time we spend in our workplace, the line between personal and working relationships can be blurrier, she says. When a person feels more like a friend, you can feel a stronger sense of loyalty to them as opposed to if they were just a coworker. So it can be understandable that you dont want your friend to get in trouble if you sense their performance slipping. You may even feel inclined to pick up their slack. I believe that this is a mistakebecause if you do decide to pick up their slack, you are essentially enabling their behavior, explains Stockard. It communicates to your friend that they do not have to follow through with their responsibilities, because you will end up doing it. Deciding whether to raise your concerns is a personal decision. And if theres no change after a direct conversation, it might be time to escalate, because your responsibility is to the team and organization, not just the friendship, says Jonathan Alpert, a New York City- and Washington, D.C.-based psychotherapist. But do it professionally. Document examples of poor performance and inform your supervisor without framing it as a personal gripe, he continues. Focus on facts and team impact. This prevents resentment from building and puts the issue where it belongswith management.” Also, understand that friendship adds a layer of emotional complexity. We might be afraid of damaging the relationship, being seen as overly critical, or creating tension in an otherwise enjoyable dynamic, says Alpert. Theres also an implicit expectation in friendships for loyalty and leniencywhich clashes with workplace accountability. Heres how to gently (and professionally) raise concerns with a lazy friend: Keep it private and kind. Because youre friends, have a conversation one-on-one. Avoid discussing their performance in front of others , suggests Alpert. He suggests framing your language about their work is affecting the teamnot around your feelings you might have, like frustration or impatience. Try this: When tasks slip through the cracks, it puts more pressure on the rest of us and creates stress for everyone. This keeps the conversation professional and objective, Alpert says. Understand their work method isnt exactly like yours. Its important to recognize that you can only control yourself. Just because someone has a separate work ethic than you, it does not necessarily mean that theirs is wrong, Stockard explains. She says if their work is indeed directly impacting yours, you can discuss with them how their work ethic is negatively impacting you, and what could be some constructive ways to make your lives easier. Separate your personal relationship with your work relationship by making it clear that you do not want their accountability at work to influence your friendship, Stockard adds. And that before things impact your personal relationship, you want to discuss your work issues. Consider a lighter approach. Because of your friendship, a lighthearted comment could be an easier way to bring up your concerns. You can make a lighthearted comment about working harder than your friendor how your back hurts from the weight of their slack, suggests Stockard. Delve deeper. Noticing that their performance is slipping a bit? Ask your friend if something else is going on. If this behavior is uncommon for your friend, or that it has gotten worse over time, I would recommend asking your friend how they are doing, or if anything is going on in their personal life that might be impacting their ability to do their job, recommends Stockard. If you feel available to assist them while they are going through this, make sure you clearly communicate boundaries about what you are or are not willing to do. Despite the fact your colleague is cool or fun to grab lunch or gossip with, it can be bad for you if their output is dragging the team down, either intentionally or unintentionally. It can be uncomfortable to share your concerns about their work ethic, but in the long run, its better to speak up. (You can joke about it at happy hour later.)
Category:
E-Commerce
Some of the most ambitious cancer science is happening in a disease few outside of oncology can name, and its revealing a future where cancer is no longer a death sentence. Multiple myeloma (MM) is a blood cancer that affects the bodys plasma cells, causing them to mutate and grow uncontrollably in the bone marrow. These plasma cells produce abnormal antibodies called M-proteins that wreak havoc on the immune system, kidneys, and bones. MM is also relatively rare. While breast cancer saw approximately 370,000 new cases in the U.S. in 2024, multiple myeloma only saw about 31,600, per internal data from Evaluate. Even among blood cancers, MM only makes up 10% of cases. Yet, despite its rarity, multiple myeloma has become a springboard for some of the most advanced drug innovations in cancer, fostering the development of advanced gene therapies and antibody technologies. While new breakthroughs extend MM patients lifespans, treatment for the disease is exposing a new reality of navigating cancer as a chronic, high-cost condition. MYELOMAS MANY INNOVATIONS Despite only making up less than 2% of cancer diagnoses, multiple myeloma has seen an array of breakthrough treatments that have more than doubled its five-year relative survival rate since 1990. These include: Stem cell transplants, which use a patients own stem cells to rebuild healthy bone marrow after intense chemotherapy targeting cancer in the bone marrow itself Proteasome inhibitors, which kill myeloma cells by interfering with the normal break down of proteins Immunomodulatory drugs (IMiDs), which stimulate the immune system and eliminate proteins essential for the survival of myeloma cells Chimeric antigen receptor T cells (CAR-Ts), which custom-engineer a patients own T cells to target and destroy malignant plasma cells Bispecific antibodies (bispecifics), which redirect T cells to kill malignant plasma cells by bringing the two cells in close proximity Monoclonal antibodies, which precisely target specific proteins on cancer cells or in the tumor environment, and are behind some of the most promising survivability gains Though not the first cancer to see some of these novel treatments, MM is one of the first diseases to achieve approval for CAR-Ts, bispecifics, and monoclonal antibodies all at the same time. Its unique attributes unlock innovation, driving $24 billion in U.S. drug sales in 2024 alone, per Evaluate internal data. MMS UNIQUE ADVANTAGES Multiple myeloma has four key advantages that make it a sandbox for cancer innovation. MM has a high survival rate. Non-small cell lung cancer (NSCLC)one of the most common cancershas a five-year survival rate of 32% across all stages; multiple myelomas is 62%, with a median patient survival length of 810 years. Longer survival creates a bigger window to offer multiple treatments. Multiple myeloma comes with its own accelerometer. The M-protein biomarker rises and falls quickly, offering a clear sign of the cancers progression and response to treatment. Consequently, trials to develop new multiple myeloma medications show efficacy faster, so are less expensive than those for most other cancer drugs. MM can be almost completely eradicated from the body. In 2024, MM became the first cancer for which the FDA endorsed minimum residual disease as a surrogate goal or endpoint for drug trials, which qualifies many MM drugs for breakthrough therapy designation or accelerated approval. Multiple myeloma received approval for seven new drugs between 2020 and 2022, including multiple first-in-class therapies. This surge in innovation, rarely seen in oncology, is likely to continue now that minimal residual disease is accepted as a surrogate endpoint. The incentives for developers to create new MM drugs are strong. Unlike other rare diseases whose treatments only incrementally increase survival, MM treatments drastically improve length and quality of life. The latest combination of drugs being tested to treat MM has been modeled to increase survival without disease progression by a full decade among healthier patients. As a result, MM patients are more likely to spend on high-cost drug regimens to keep the disease at bay, further funding research. Multiple myelomas ability to foster innovation drives comparatively lofty drug sales for its rarity. Evaluates internal data shows that, in 2024, non-small cell lung cancer (NSCLC) saw about six times more new cases than MM, yet NSCLC drugs only brought in a third more revenue than MM drugs did that year. Drugmakers are looking to re-create MMs success in other cancers, but its innovations have proven difficult to reproduce. REPLICATING MMS ADVANCEMENTS Multiple myeloma drugs have proven more effective because they can directly reach the diseases liquid tumors within the bloodstream. In contrast, other cancers solid tumors are embedded in dense, immunosuppressive tissue environments that can be difficult for drugs to access. Furthermore, solid tumors often lack good cell surface targets that differentiate them from surrouning healthy cells. Many companies have tried to apply MMs breakthroughs to other cancers and a few are beginning to see success in solid tumors. Gileads CAR-T therapy is showing promise in shrinking deadly brain cancer tumors, while bispecifics are beginning to show promise in treating small cell lung cancer. The trick for scientists now is to take the base-level innovations that have worked in MM and apply them with more specified targeting, delivery, and immune activation to other cancers. Meanwhile, the treatment innovations MM patients enjoy also bring new, unintended consequences. CANCERS CHRONIC FUTURE Multiple myeloma reveals a future where cancer patients not only live longer but also shoulder continual treatment expenses. A study examining Medicare claims from 20062016 found the average lifetime treatment costs for MM were $184,495, and out-of-pocket costs have only increased since then. As a result, one in four patients with MM experience financial hardship due to treatment costs, causing some to skip doses or delay care. Despite already high treatment costs, myeloma therapies continue to increase in price. Evaluates internal data reveals that Medicare coinsurance patients can expect to pay $105,700 out of pocket for cutting-edge CAR-T Carvykti. However, even the price for the most widely prescribed MM drug, Revlimid, has increased 17% in the last four years, notwithstanding cheaper, generic versions of the drug beginning to roll out in 2022. To make long-term cancer survival a viable reality for more patients, drugmakers will have to iterate on MMs playbook while U.S. hospital systems and insurance companies make innovations more accessible at scale. In the meantime, we can glimpse into the future of cancer treatment in multiple myeloma, where breakthroughs are making long-term survival the new normal. Soon, MMs innovations will spur discoveries that extend the lives of all cancer patients.
Category:
E-Commerce
All news |
||||||||||||||||||
|
||||||||||||||||||